Table 2 Clinical anti-tumor activity summary

From: Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation

 

Monotherapy cohort (n = 26)

Combination cohort (n = 42)

Time to Response (Months)

 Median

2.6

1.7

 Min, Max

1.4, 5.5

1.2, 13.8

Best Overall Response, n (%)

 Complete response

1 (3.8)

1 (2.4)

 Partial response

4 (15.4)

18 (42.9)

 Stable disease

19 (73.1)

20 (47.6)

 Progressive disease

2 (7.1)

2 (4.8)

 Unable to evaluate

0

1 (2.4)

Disease control rate, n (%)

24 (92.3)

39 (92.9)

 95% CI

74.9, 99.1

80.5, 98.5

Confirmed objective response rate, n (%)

5 (19.2)

19 (45.2)

 95% CI

6.6, 39.4

29.8, 61.3

Median duration of response, months

10.3

8.2

 95% CI

2.7, NE

4.2, NE

Median progression-free survival, months

5.5

7.5

 95% CI

2.9, 11.6

5.5, 8.1

Median overall survival, months

13.1

Not reached

 95% CI

9.5, NE

11.3, NE

Back to article page